Edition:
India

Shire PLC (SHP.L)

SHP.L on London Stock Exchange

4,442.50GBp
17 Aug 2018
Change (% chg)

-0.50 (-0.01%)
Prev Close
4,443.00
Open
4,443.00
Day's High
4,450.00
Day's Low
4,427.50
Volume
1,081,743
Avg. Vol
3,159,775
52-wk High
4,514.50
52-wk Low
2,940.50

Chart for

About

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas... (more)

Overall

Beta: 1.54
Market Cap(Mil.): £35,231.62
Shares Outstanding(Mil.): 908.51
Dividend: 3.85
Yield (%): --

Financials

  SHP.L Industry Sector
P/E (TTM): 66.92 30.93 32.76
EPS (TTM): 0.58 -- --
ROI: 1.15 15.07 14.61
ROE: 2.31 16.59 16.33

Shire profit edges higher ahead of Takeda sale

LONDON Shire , the London-listed pharmaceutical group being bought by Japan's Takeda , reported a 4 percent rise in second-quarter earnings as revenue rose 5 percent to $3.92 billion, just ahead of market expectations.

31 Jul 2018

UPDATE 1-Shire profit edges higher ahead of Takeda sale

LONDON, July 31 Shire, the London-listed pharmaceutical group being bought by Japan's Takeda, reported a 4 percent rise in second-quarter earnings as revenue rose 5 percent to $3.92 billion, just ahead of market expectations.

31 Jul 2018

Shire posts 4 pct rise in Q2 earnings ahead of sale to Takeda

LONDON, July 31 Shire, the London-listed pharmaceutical group being bought by Japan's Takeda, reported a 4 percent rise in second-quarter earnings as revenue rose 5 percent to $3.92 billion, just ahead of market expectations.

31 Jul 2018

UPDATE 2-Takeda operating profit halves, looks to asset sales to shore up finances

* Shire-related costs helped push debt ratio higher (Adds details from news conference)

31 Jul 2018

Buy yen in crisis? Not this year

LONDON/TOKYO The trade is familiar to investors worldwide: in times of turmoil, rush for cover by buying the Japanese yen.

24 Jul 2018

Japan's Takeda gains U.S. approval for $62 billion Shire buy

TOKYO Takeda Pharmaceutical Co Ltd on Tuesday said it has received U.S. approval for its $62 billion acquisition of London-listed Shire Plc, taking the Japanese firm one step closer to its goal of becoming a global top 10 drugmaker.

10 Jul 2018

UPDATE 2-Japan's Takeda gains US approval for $62 bln Shire buy

* Also needs approval from Takeda, Shire shareholders (Adds share movement)

10 Jul 2018

Takeda gets key U.S. regulatory approval to buy Shire

TOKYO, July 10 Japan's Takeda Pharmaceutical Co Ltd said on Tuesday it received a key U.S. regulatory approval for its $62 billion deal to buy London-listed Shire Plc .

10 Jul 2018

Japan's Takeda to sell Osaka headquarters, could raise 60 billion yen: Nikkei

TOKYO Japan's Takeda Pharmaceutical Co Ltd is selling its Osaka headquarters amid concerns over its finances due to its $62 billion deal to buy London-listed Shire Plc , the Nikkei business daily reported on Thursday.

05 Jul 2018

Japan's Takeda to sell Osaka headquarters, could raise Y60 bln - Nikkei

TOKYO, July 5 Japan's Takeda Pharmaceutical Co Ltd is selling its Osaka headquarters amid concerns over its finances due to its $62 billion deal to buy London-listed Shire Plc, the Nikkei business daily reported on Thursday.

05 Jul 2018

Earnings vs. Estimates